Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183041 | 0.88 | KDM4E (0.36) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12376780 | 0.76 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10P2RX7 | |
| SCHEMBL22102661 | 0.75 | — | — | |
| SCHEMBL10183608 | 0.71 | GSK3B (0.34) | — | |
| SCHEMBL14459758 | 0.67 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10P2RX7 | |
| SCHEMBL10183038 | 0.64 | AR (0.44) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22102449 | 0.64 | GFER (0.42) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10183114 | 0.64 | — | — | |
| SCHEMBL10183044 | 0.63 | MAPK1 (0.47) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10183047 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 2722/4885ALDH1A1 1934/4885HPGD 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.